GENERAL, O. Reg. 246/22

Section 124

Quarterly evaluation

Cite as GENERAL, O. Reg. 246/22, s. 124 · current to November 11, 2026 · consolidated from January 1, 2026 · read from e-Laws on November 16, 2026

The text

(1) Every licensee of a long-term care home shall ensure that an interdisciplinary team, which must include the Medical Director, the Administrator, the Director of Nursing and Personal Care and the pharmacy service provider, meets at least quarterly to evaluate the effectiveness of the medication management system in the home and to recommend any changes necessary to improve the system. O. Reg. 246/22, s. 124 (1). (2) Where the pharmacy service provider is a corporation, the licensee shall ensure that a pharmacist from the pharmacy service provider participates in the quarterly evaluation. O. Reg. 246/22, s. 124 (2). (3) The quarterly evaluation of the medication management system must include at least, (a) reviewing drug utilization trends and drug utilization patterns in the home, including the use of any drug or combination of drugs, including psychotropic drugs, that could potentially place residents at risk; (b) reviewing reports of any medication incidents, any incidents of severe hypoglycemia and unresponsive hypoglycemia, the use of glucagon and adverse drug reactions referred to in subsections 147 (2) and (3), the factors that contributed to the incident, use of glucagon or drug reaction and all instances of the restraining of residents by the administration of a drug when immediate action is necessary to prevent serious bodily harm to a resident or to others pursuant to the common law duty referred to in section 39 of the Act; and (c) identifying changes to improve the system in accordance with evidence-based practices and, if there are none, in accordance with prevailing practices. O. Reg. 246/22, s. 124 (3); O. Reg. 66/23, s. 25 (1). (3.1) For the purposes of clause (3) (a), and without limiting the generality of this section, the review of drug utilization trends and drug utilization patterns in the home must include trends and patterns associated with the use of glucagon in the home. O. Reg. 66/23, s. 25 (2). (4) The licensee shall ensure that the changes identified in the quarterly evaluation are implemented. O. Reg. 246/22, s. 124 (4). (5) The licensee shall ensure that a written record is kept of the results of the quarterly evaluation and of any changes that were implemented. O. Reg. 246/22, s. 124 (5).
Read the GENERAL on e-Laws ↗

Made under Fixing Long-Term Care Act, 2021, S.O. 2021, c. 39, Sched. 1.